Methods of identifying and treating glioblastoma
The invention encompasses methods and kits used in the detection of invasive glioblastoma based upon the expression of NHERF-1. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
1. A method of sensitizing a subject diagnosed with invasive cancer to a therapeutic that targets non-migrating cells, the method comprising the step of administering to the subject a NHERF1 (SEQ ID NO:1 or SEQ ID NO:2) inhibitor wherein the inhibition of NHERF1 switches invasive cancer cells in the subject to non-migrating cancer cells that are sensitive to a therapeutic that targets the non-migrating cells.
2. The method of claim 1 , wherein the therapeutic is selected from the group consisting of Temozolomide and bevacizumab.
3. The method of claim 1 , wherein the NHERF1 inhibitor is an siRNA against the nucleotide sequence of SEQ ID NO:1.
4. The method of claim 3 , wherein the NHERF1 inhibitor is selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
5. The method of claim 1 , wherein the invasive cancer is selected from the group consisting of glioblastoma, breast cancer, and hepatocellular carcinoma.
6. A method of treating invasive cancer in a subject, the method comprising the steps of:
administering to the subject a NHERF1 (SEQ ID NO:1 or SEQ ID NO:2) inhibitor that switches invasive cancer cells to non-migrating cancer cells; and
administering a chemotherapeutic agent.
7. The method of claim 6 , wherein the NHERF1 inhibitor is an siRNA against the nucleotide sequence of SEQ ID NO:1.
8. The method of claim 7 , wherein the NHERF1 inhibitor is selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
9. The method of claim 6 , wherein the chemotherapeutic agent is selected from the group consisting of Temozolomide and bevacizumab.
10. The method of claim 6 , wherein the invasive cancer is selected from the group consisting of glioblastoma, breast cancer, and hepatocellular carcinoma.
11. A method of inhibiting the migration of cancer cells in a subject, the method comprising the step of administering to the subject a NHERF1 (SEQ ID NO:1 or SEQ ID NO:2) inhibitor.
12. The method of claim 11 , wherein the NHERF1 inhibitor 1 is an siRNA against the nucleotide sequence of SEQ ID NO:1.
13. The method of claim 11 , wherein the NHERF1 inhibitor is selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
14. The method of claim 11 , wherein the cancer cells is selected from the group consisting of glioblastoma, breast cancer, and hepatocellular carcinoma.
15. The method of claim 9 , wherein inhibiting the migration of cancer cells also sensitizes the cancer cells to a chemotherapeutic agent.